Acumen Pharmaceuticals, Inc.

Healthcare · Biotechnology · United States

Last price 0.2101 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 15.20M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development o...